We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Comparative Effectiveness of COVID-19 Vaccines in Preventing Infections and Disease Progression from SARS-CoV-2 Omicron BA.5 and BA.2, Portugal.
- Authors
Kislaya, Irina; Casaca, Pedro; Borges, Vítor; Sousa, Carlos; Ferreira, Bibiana I.; Fonte, Ana; Fernandes, Eugénia; Matias Dias, Carlos; Duarte, Sílvia; Pedro Almeida, José; Grenho, Inês; Coelho, Luís; Ferreira, Rita; Pita Ferreira, Patrícia; Medeiros Borges, Cláudia; Isidro, Joana; Pinto, Miguel; Menezes, Luís; Sobral, Daniel; Nunes, Alexandra
- Abstract
We estimated comparative primary and booster vaccine effectiveness (VE) of SARS-CoV-2 Omicron BA.5 and BA.2 lineages against infection and disease progression. During April–June 2022, we implemented a case–case and cohort study and classified lineages using wholegenome sequencing or spike gene target failure. For the case–case study, we estimated the adjusted odds ratios (aORs) of vaccination using a logistic regression. For the cohort study, we estimated VE against disease progression using a penalized logistic regression. We observed no reduced VE for primary (aOR 1.07 [95% CI 0.93–1.23]) or booster (aOR 0.96 [95% CI 0.84–1.09]) vaccination against BA.5 infection. Among BA.5 case-patients, booster VE against progression to hospitalization was lower than that among BA.2 case-patients (VE 77% [95% CI 49%–90%] vs. VE 93% [95% CI 86%–97%]). Although booster vaccination is less effective against BA.5 than against BA.2, it offers substantial protection against progression from BA.5 infection to severe disease.
- Subjects
PORTUGAL; SARS-CoV-2 Omicron variant; VACCINE effectiveness; COVID-19 vaccines; DISEASE progression; BOOSTER vaccines
- Publication
Emerging Infectious Diseases, 2023, Vol 29, Issue 3, p569
- ISSN
1080-6040
- Publication type
Article
- DOI
10.3201/eid2903.221367